1. Home
  2. MPU vs NXTC Comparison

MPU vs NXTC Comparison

Compare MPU & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MPU

Mega Matrix Corp.

HOLD

Current Price

$0.50

Market Cap

44.8M

ML Signal

HOLD

Logo NextCure Inc.

NXTC

NextCure Inc.

N/A

Current Price

$9.95

Market Cap

39.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MPU
NXTC
Founded
1989
2015
Country
Singapore
United States
Employees
N/A
N/A
Industry
Transportation Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.8M
39.1M
IPO Year
2023
2019

Fundamental Metrics

Financial Performance
Metric
MPU
NXTC
Price
$0.50
$9.95
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$23.00
AVG Volume (30 Days)
37.0K
53.0K
Earning Date
04-16-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$22,378,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$0.42
52 Week High
$4.44
$15.74

Technical Indicators

Market Signals
Indicator
MPU
NXTC
Relative Strength Index (RSI) 32.74 45.63
Support Level N/A $8.45
Resistance Level $0.78 $10.81
Average True Range (ATR) 0.06 0.82
MACD -0.00 0.02
Stochastic Oscillator 0.11 39.33

Price Performance

Historical Comparison
MPU
NXTC

About MPU Mega Matrix Corp.

Mega Matrix Inc is a holding company. It operates through its two subsidiaries Mega Metaverse Corp (Mega) and JetFleet Management Corp (JMC). The Company has two business segments which are comprised of : ETH staking business and The leasing of regional aircraft to foreign and domestic regional airlines. The majority of the company's revenue is earned through Leasing business segment. The company operates in USA and Canada, Asia-Pacific, Europe, Middle East and Africa, and Latin America.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: